Education
About Us
Working with TipRanks
Follow Us
Kala Pharmaceuticals Inc (KALA)
NASDAQ:KALA
Total Valuation
Kala Pharmaceuticals has a market cap or net worth of $23.68M. The enterprise value is $3.14M.
Market Cap$23.68M
Enterprise Value$3.14M
Share Statistics
Kala Pharmaceuticals has 6,452,398 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,452,398
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kala Pharmaceuticals’s return on equity (ROE) is -3.12 and return on invested capital (ROIC) is -83.23%.
Return on Equity (ROE)-3.12
Return on Assets (ROA)-0.69
Return on Invested Capital (ROIC)-83.23%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee0.00
Profits Per Employee-1.01M
Employee Count38
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kala Pharmaceuticals is -6.84. Kala Pharmaceuticals’s PEG ratio is -0.04.
PE Ratio-6.84
PS Ratio0.00
PB Ratio1.30
Price to Fair Value21.36
Price to FCF-0.75
Price to Operating Cash Flow-0.55
PEG Ratio-0.04
Income Statement
In the last 12 months, Kala Pharmaceuticals had revenue of 0.00 and earned -38.51M in profits. Earnings per share was -1.01.
Revenue0.00
Gross Profit0.00
Operating Income-40.98M
Pretax Income-38.51M
Net Income-38.51M
EBITDA-40.98M
Earnings Per Share (EPS)-1.01
Cash Flow
In the last 12 months, operating cash flow was -29.38M and capital expenditures -69.00K, giving a free cash flow of -29.45M billion.
Operating Cash Flow-29.38M
Free Cash Flow-29.45M
Free Cash Flow per Share-4.56
Dividends & Yields
Kala Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.06
52-Week Price Change-44.65%
50-Day Moving Average4.70
200-Day Moving Average6.17
Relative Strength Index (RSI)46.78
Average Volume (3m)81.18K
Important Dates
Kala Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Kala Pharmaceuticals as a current ratio of 3.11, with Debt / Equity ratio of 261.53%
Current Ratio3.11
Quick Ratio3.11
Debt to Market Cap0.12
Net Debt to EBITDA0.46
Interest Coverage Ratio7.09
Taxes
In the past 12 months, Kala Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kala Pharmaceuticals EV to EBITDA ratio is -5.97, with an EV/FCF ratio of -8.26.
EV to Sales0.00
EV to EBITDA-5.97
EV to Free Cash Flow-8.26
EV to Operating Cash Flow-8.32
Balance Sheet
Kala Pharmaceuticals has $51.18M in cash and marketable securities with $32.25M in debt, giving a net cash position of -$18.93M billion.
Cash & Marketable Securities$51.18M
Total Debt$32.25M
Net Cash-$18.93M
Net Cash Per Share-$2.93
Tangible Book Value Per Share$0.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kala Pharmaceuticals is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside308.72% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast38.50%